

Terumo Announces Voting Results for the Election of Directors

TOKYO, JAPAN – June 22, 2022 – Terumo Corporation (TSE: 4543) hereby announces the voting results for the election of directors held at the Annual General Meeting of Shareholders today. All eight of the candidates listed on May 12 were elected as directors of Terumo Corporation. The three directors serving as Audit and Supervisory Committee members, elected on June 22, 2021, continue to hold office.

1. Directors

(Excluding directors who serve as Audit/Supervisory Committee Members)

Name	New position	Current position
Toshiaki Takagi	Chairman of the Board	Same as on the left
Shinjiro Sato	President and CEO	Same as on the left
Shoji Hatano	Director and Group Senior Managing Executive Officer	Same as on the left
Kyo Nishikawa	Director and Group Managing Executive Officer	Same as on the left
Kazunori Hirose	Director and Group Managing Executive Officer	Group Managing Executive Officer
Yukiko Kuroda	Independent Director	Same as on the left
Hidenori Nishi	Independent Director	Same as on the left
Keiya Ozawa	Independent Director	Same as on the left

2. Directors who serve as Audit/Supervisory Committee Members

Name	New position	Current position
Takanori Shibazaki	Director who serves as an Audit/Supervisory Committee Member	Same as on the left
Masaichi Nakamura	Independent Director who serves as an Audit/Supervisory Committee Member	Same as on the left
Soichiro Uno	Independent Director who serves as an Audit/Supervisory Committee Member	Same as on the left

About Terumo

Terumo (TSE:4543) is a global leader in medical technology and has been committed to "Contributing to Society through Healthcare" for 100 years. Based in Tokyo and operating globally, Terumo employs more than 25,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice. Terumo will further strive to be of value to patients, medical professionals, and society at large.